Abstract
Currently in Mexico, the available clinical guidelines published for COVID-19 treatment recommend symptom treatment and home isolation for mild forms; and other medications for severe and acute forms. The effectiveness of how real-world treatment patterns impact mortality and recovery is still unknown. In this retrospective observational study, we investigated 5,575 medicated patients with COVID-19 treated at two Mexican states seen in the largest healthcare system in Mexico. A survival analysis was performed using death and discharge as primary and secondary outcomes (respectively). Machine learning models were built to predict mortality and discharge. The higher prevalence of obesity, diabetes, and heart disease comorbidities is consistent with Mexico’s epidemiological profile. Mortality occurs around 15-20 days from the start of symptoms. Antivirals in combination with antibiotics present lower survival rates, with patients undertaking neuraminidase inhibitors (NAIs) being the most affected. Our findings recommend against using specific treatment combinations with NAIs, and should help improve the country’s clinical guidelines.
Competing Interest Statement
GGA, CAA and ALP declare to work at Amphora Health. ALP declares to hold shares at Amphora Health. CDB is on the scientific advisory boards of AncestryDNA, ArcBio LLC, Etalon DX, Liberty Biosecurity, Personalis, EdenRoc Sciences LLC. CDB and SMG declare to work at Galatea Bio. GGA and ALP are contractors at Galatea Bio. CDB declares to hold shares at Galatea Bio. The remaining authors declare that there is no conflict of interest regarding the publication of this article.
Funding Statement
Research reported in this publication was partially supported via institutional funds from each participant institution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics and Research Committees from the Mexican Institute of Social Security (IMSS), which are certified as Institutional Review Board (IRB) in accordance with the Mexican regulation, under protocol numbers R-2021-1912-014, R-2020-785-058.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that supports the findings of this study is available for research purposes upon written request, which will be reviewed on a case-by-case basis by IMSS IRB given the submission of a research protocol.
